OPTI Stock Overview
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulators primarily in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
OptiBiotix Health Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.18 |
| 52 Week High | UK£0.43 |
| 52 Week Low | UK£0.056 |
| Beta | 1.58 |
| 1 Month Change | -25.26% |
| 3 Month Change | -29.70% |
| 1 Year Change | 73.17% |
| 3 Year Change | -65.20% |
| 5 Year Change | -75.68% |
| Change since IPO | 97.22% |
Recent News & Updates
Shareholder Returns
| OPTI | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -5.3% | -1.9% | -0.9% |
| 1Y | 73.2% | -30.5% | -1.8% |
Return vs Industry: OPTI exceeded the UK Biotechs industry which returned -30.5% over the past year.
Return vs Market: OPTI exceeded the UK Market which returned -1.8% over the past year.
Price Volatility
| OPTI volatility | |
|---|---|
| OPTI Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: OPTI's share price has been volatile over the past 3 months.
Volatility Over Time: OPTI's weekly volatility has decreased from 17% to 9% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 9 | Stephen O'Hara | www.optibiotix.com |
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; SlimBiome Medical, a natural supplement for weight management; CholBiome, a food supplement for maintaining healthy levels of cholesterol; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galactooligosaccharid that is used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; and Sweetbiotix, a sweetener for use in food and beverages.
OptiBiotix Health Plc Fundamentals Summary
| OPTI fundamental statistics | |
|---|---|
| Market cap | UK£17.38m |
| Earnings (TTM) | -UK£13.17m |
| Revenue (TTM) | UK£689.00k |
25.2x
P/S Ratio-1.3x
P/E RatioIs OPTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPTI income statement (TTM) | |
|---|---|
| Revenue | UK£689.00k |
| Cost of Revenue | UK£349.00k |
| Gross Profit | UK£340.00k |
| Other Expenses | UK£13.52m |
| Earnings | -UK£13.17m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 49.35% |
| Net Profit Margin | -1,912.19% |
| Debt/Equity Ratio | 0% |
How did OPTI perform over the long term?
See historical performance and comparison